Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly injection could help shed pounds without diabetes

NCT ID NCT07232719

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a once-weekly injection called retatrutide to help people with obesity or overweight lose weight. About 250 participants without type 2 diabetes will receive either the drug or a placebo for 65 weeks. The main goal is to see how much weight they lose and if it is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
retatrutide
What this could lead to
If it works, this could provide a new weekly injection to help people with obesity or overweight lose significant body weight.
What could go wrong
This is a phase 3 trial, but results are not yet known. The drug may cause side effects, and weight loss may vary. It is not a cure for obesity, and long-term use may be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a body mass index (BMI) of: * ≥30 kilogram per square meter (kg/m2) OR * ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kg (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Albany House Medical Centre

    Wellingborough, NN8 4RW, United Kingdom

  • Artemis Institute for Clinical Research

    Riverside, California, 92503, United States

  • Atlantic Medical

    Penzance, TR18 3DX, United Kingdom

  • Bradford on Avon Health Centre

    Bradford-on-Avon, BA15 1DQ, United Kingdom

  • Care Access - Arlington Heights

    Arlington Heights, Illinois, 60005, United States

  • Care Access - Houston

    Houston, Texas, 77054, United States

  • Care Access - Tamarac

    Tamarac, Florida, 33321, United States

  • Cedar Health Research

    Dallas, Texas, 75251, United States

  • Cedar Health Research - Euless

    Euless, Texas, 76040, United States

  • Cedar Health Research - Fort Worth

    Fort Worth, Texas, 76132, United States

  • Cheadle Community Hospital

    Cheadle, ST10 1NS, United Kingdom

  • Clinical Research Professionals

    Chesterfield, Missouri, 63005, United States

  • Clinvest Headlands Llc

    Springfield, Missouri, 65807, United States

  • FutureMeds - Birmingham

    Birmingham, B21 9RY, United Kingdom

  • FutureMeds - Liverpool

    Bromborough, CH62 6EE, United Kingdom

  • HMC Health Group - Meadows Centre for Health

    Hounslow, TW4 7NR, United Kingdom

  • Headlands Research Orlando

    Orlando, Florida, 32806, United States

  • Headlands Research-El Paso

    El Paso, Texas, 79902, United States

  • IMA Clinical Research Manhattan

    New York, New York, 10036, United States

  • IMA Clinical Research Monroe - Armand

    Monroe, Louisiana, 71201, United States

  • IMA Clinical Research San Antonio

    San Antonio, Texas, 78229, United States

  • IMA Clinical Research Warren

    Warren Township, New Jersey, 07059, United States

  • JEM Research Institute

    Atlantis, Florida, 33462, United States

  • L-MARC Research Center

    Louisville, Kentucky, 40213, United States

  • Layton Medical Centre

    Blackpool, FY3 7EN, United Kingdom

  • Pharmasite Research, Inc.

    Baltimore, Maryland, 21208, United States

  • Rame Group Practice

    Torpoint, PL11 2TB, United Kingdom

  • St Bartholomew's Medical Centre

    Oxford, OX4 1XB, United Kingdom

  • The Adam Practice

    Poole, BH16 5PW, United Kingdom

  • Trial Management Associates - Wilmington - Floral Parkway

    Wilmington, North Carolina, 28403, United States

  • Woodstock Bower Surgery

    Rotherham, S61 1AH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.